ASGCT News   |   Funding

Gene, Cell, & RNA Therapy Landscape: Q1 2021

David M. Barrett, J.D., M.S. - April 15, 2021

The first of a new, quarterly publication from ASGCT, the Gene, Cell, & RNA Therapy Landscape report is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.

ASGCT has partnered with Informa Pharma Intelligence to provide a data-driven, comprehensive look at clinical and pre-clinical progress across gene and cell therapies throughout the world to our members, and to the community at large.

Read the Full Report

This collection of reports will grow over time to show the expansion of the field, reflect clinical progress, and reveal patterns in therapeutic areas under development.

To that end, the data show unequivocally that gene, cell, and RNA therapies continue to grow rapidly with nearly 3,500 therapies in preclinical and clinical development throughout the world. While the overwhelming majority of therapies target cancers, there are currently 77 therapies in Phase III clinical trials across all gene, cell, and RNA therapies.

Also impressive is the nearly $480M in start-up financing which has been invested across 13 companies throughout the gene, cell, and RNA therapeutics industry in the first quarter of 2021.

ASGCT appreciates the input of our data partners at Informa Pharma Intelligence for assisting in the collection and curation of this revealing information.  We look forward to your response to this and future reports as we identify trends and provide deeper analysis of the underlying data.

Click any of the samples below to view the full report:




David M. Barrett, JD, MS is the Chief Executive Officer of the American Society of Gene & Cell Therapy

Related Articles


Dr. Terence Flotte Calls for CGT Investment and Collaboration During Congressional Testimony

Read Dr. Flotte's testimony + watch the hearing - February 29, 2024

Mohamed Abou-el-Enein Appointed Editor of Molecular Therapy Methods and Clinical Development

Dr. Abou-el-Enein began five-year term Jan. 1. - January 04, 2024

For Members, ASGCT Has More Programming, Research Funding, and Opportunities Than Ever

Join the largest CGT community - October 03, 2023

Drew Weissman & Katalin Karikó to Co-Receive 2023 Nobel Prize for Discoveries in mRNA Technology

October 02, 2023